

- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res* 1988;48:3282–3287.
- Ercal HS, Mendenhall WM, Amdur RJ, et al. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. *J Clin Oncol* 2001;19:1358–1362.
- Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. *Cancer* 1953;6:963–968.
- Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000;92:709–720.
- Mendenhall WM, Logan HL. Human papillomavirus and head and neck cancer. *Am J Clin Oncol* 2009;32:535–539.
- Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. *J Clin Oncol* 2006;24:5630–5636.
- Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363:24–35.
- Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. *J Clin Oncol* 2012;30:2102–2111.
- Patel SC, Carpenter WR, Tyree S, et al. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. *J Clin Oncol* 2011;29:1488–1494.
- Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. *Semin Cancer Biol* 2002;12:421–429.
- Luce D, Gerin M, Leclere A, et al. Sinonasal cancer and occupational exposure to formaldehyde and other substances. *Int J Cancer* 1993;53:224–231.
- Rouvière H. *Anatomy of the Human Lymphatic System*. Arbor, MI: Edwards Brothers; 1938.
- McAfee WJ, Morris CG, Amdur RJ, et al. Definitive radiotherapy for juvenile nasopharyngeal angiofibroma. *Am J Clin Oncol* 2006;29:168–170.
- Ward JR, Feigenberg SJ, Mendenhall NP, et al. Radiation therapy for angiosarcoma. *Head Neck* 2003;25:873–878.
- Chen SA, Morris CG, Amdur RJ, et al. Adult head and neck soft tissue sarcoma. *Am J Clin Oncol* 2005;28:259–263.
- Maddox WA, Urist MM. Histopathological prognostic factors of certain primary oral cavity cancers. *Oncology (Williston Park)* 1990;4:39–42.
- Cianchetti M, Mancuso AA, Amdur RJ, et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. *Laryngoscope* 2009;119:2348–2354.
- Ercal HS, Mendenhall WM, Amdur RJ, et al. Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head-and-neck mucosal site treated with radiation therapy alone or in combination with neck dissection. *Int J Radiat Oncol Biol Phys* 2001;50:55–63.
- Lindberg RD. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. *Cancer* 1972;29:1446–1449.
- Fisch U. *Lymphography of the Cervical Lymphatic System*. Philadelphia: W. B. Saunders; 1968.
- McLaughlin MP, Mendenhall WM, Mancuso AA, et al. Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck. *Head Neck* 1995;17:190–198.
- Al-Othman MO, Morris CG, Hinerman RW, et al. Distant metastases after definitive radiotherapy for squamous cell carcinoma of the head and neck. *Head Neck* 2003;25:629–633.
- Merino OR, Lindberg RD, Fletcher GH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. *Cancer* 1977;40:145–151.
- Hinerman RW, Amdur RJ, Morris CG, et al. Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. *Head Neck* 2008;30:1431–1438.
- Edge SB, Byrd DR, Compton CC, eds. *AJCC Cancer Staging Handbook*. 7th ed. New York: Springer; 2010.
- Mendenhall WM, Parsons JT, Million RR, et al. A favorable subset of AJCC stage IV squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 1984;10:1841–1843.
- Koefman SA, Adelstein DJ. Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review. *Int J Radiat Oncol Biol Phys* 2012;84:581–589.
- Trotti A, Fu KK, Pajak TF, et al. Long term outcomes of RTOG 90-03: A comparison of hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2005;63:S70–S71.
- Mendenhall WM, Riggs CE, Vaysberg M, et al. Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma. *Head Neck* 2010;32:939–945.
- Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. *J Clin Oncol* 2006;24:2618–2623.
- Mendenhall WM, Mancuso AA. Radiotherapy for head and neck cancer—the “next level” down? *Int J Radiat Oncol Biol Phys* 2009;73:645–646.
- Schoenfeld GO, Amdur RJ, Morris CG, et al. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. *Int J Radiat Oncol Biol Phys* 2008;71:377–385.
- Nutting C, A'Hern R, Rogers MS, et al. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). *J Clin Oncol* 2009;27:LBA6006.
- Mendenhall NP, Malyapa RS, Su Z, et al. Proton therapy for head and neck cancer: rationale, potential indications, practical considerations, and current clinical evidence. *Acta Oncol* 2011;50:763–771.
- Mendenhall WM, Villaret DB, Amdur RJ, et al. Planned neck dissection after definitive radiotherapy for squamous cell carcinoma of the head and neck. *Head Neck* 2002;24:1012–1018.
- Yeung AR, Liauw SL, Amdur RJ, et al. Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection? *Cancer* 2008;112:1076–1082.
- Pfister DG, Cassileth BR, Deng GE, et al. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. *J Clin Oncol* 2010;28:2565–2570.
- Mendenhall WM, Million RR. Elective neck irradiation for squamous cell carcinoma of the head and neck: analysis of time-dose factors and causes of failure. *Int J Radiat Oncol Biol Phys* 1986;12:741–746.
- Barkley HT Jr, Fletcher GH, Jesse RH, et al. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. *Am J Surg* 1972;124:462–467.
- O'Sullivan B, Warde P, Grice B, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. *Int J Radiat Oncol Biol Phys* 2001;51:332–343.
- Mendenhall WM, Amdur RJ, Hinerman RW, et al. Postoperative radiation therapy for squamous cell carcinoma of the head and neck. *Am J Otolaryngol* 2003;24:41–50.
- Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med* 2004;350:1945–1954.
- Bernier J, Dromeu C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med* 2004;350:1945–1952.
- Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys* 2012;84:1198–1205.
- Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. *Int J Radiat Oncol Biol Phys* 1996;36:999–1004.
- Mendenhall WM, Parsons JT, Mancuso AA, et al. Head and neck: management of the neck. In: Perez CA, Brady LW, eds. *Principles and Practice of Radiation Oncology*, 2nd ed. Philadelphia: J. B. Lippincott Company; 1992:790–805.
- Liauw SL, Mancuso AA, Amdur RJ, et al. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. *J Clin Oncol* 2006;24:1421–1427.
- Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. *J Nucl Med* 2008;49:532–540.
- McGuirt WF, McCabe BF. Significance of node biopsy before definitive treatment of cervical metastatic carcinoma. *Laryngoscope* 1978;88:594–597.
- Ellis ER, Mendenhall WM, Rao PV, et al. Incisional or excisional neck-node biopsy before definitive radiotherapy, alone or followed by neck dissection. *Head Neck* 1991;13:177–183.
- Papadimitrakopoulou VA. Chemoprevention of head and neck cancer: an update. *Curr Opin Oncol* 2002;14:318–322.
- Lippman SM, Batsakis JC, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. *N Engl J Med* 1993;328:15–20.
- Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. *N Engl J Med* 1990;323:795–801.
- Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. *J Natl Cancer Inst* 2006;98:441–450.
- Bolla M, Lefur R, Ton Van J, et al. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. *Eur J Cancer* 1994;30A:767–772.
- van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. *J Natl Cancer Inst* 2000;92:977–986.

58. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. *J Natl Cancer Inst* 2005;97:481–488.
59. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. *Clin Cancer Res* 2008;14:2095–2101.
60. Maestro R, Gasparotto D, Vukosavljevic T, et al. Three discrete regions of deletion at 3p in head and neck cancers. *Cancer Res* 1993;53:5775–5779.
61. Feng L, Wang Z. Clinical trials in chemoprevention of head and neck cancers. *Rev Recent Clin Trials* 2012;7:249–254.
62. Haddad RI, Shin DM. Recent advances in head and neck cancer. *N Engl J Med* 2008;359:1143–1154.
63. Munro AJ. Chemotherapy for head and neck cancer. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC, eds. *Oxford Textbook of Oncology*, 2nd ed. New York: Oxford University Press; 2002: 1345–1357.
64. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. *J Clin Oncol* 2006;24:2644–2652.
65. Morton RP, Rugman F, Dorman EB, et al. Cisplatin and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. *Cancer Chemother Pharmacol* 1985;15:283–289.
66. Taylor SG 4th, McGuire WP, Hauck WW, et al. A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. *J Clin Oncol* 1984;2:1006–1011.
67. Woods RL, Fox RM, Tattersall MH. Methotrexate treatment of advanced head and neck cancers: a dose response evaluation. *Cancer Treat Rep* 1981;65:155–159.
68. Schormagel JH, Verweij J, de Mulder PH, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. *J Clin Oncol* 1995;13:1649–1655.
69. Veronesi A, Zagonel V, Tirelli U, et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. *J Clin Oncol* 1985;3:1105–1108.
70. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. *Eur J Cancer* 2004;40:2071–2076.
71. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). *Cancer* 1998;82:2270–2274.
72. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. *Ann Oncol* 1994;5:495–505.
73. Couteau C, Chouaki N, Leyvraz S, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. *Br J Cancer* 1999;81:457–462.
74. Inuyama Y, Kataura A, Togawa K, et al. [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer]. *Gan To Kagaku Ryojo* 1999;26:107–116.
75. Kish JA, Ensley JF, Jacobs J, et al. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. *Cancer* 1985;56:2740–2744.
76. Rubin Grandis J, Melhem MF, Barnes EL, et al. Quantitative immunohistochemical analysis of transforming growth factor- α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. *Cancer* 1996;78:1284–1292.
77. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF- α and EGFR protein in head and neck squamous cell carcinoma and patient survival. *J Natl Cancer Inst* 1998;90:824–832.
78. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. *J Clin Oncol* 2006;24:2659–2665.
79. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. *J Clin Oncol* 2005;23:5568–5577.
80. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. *J Clin Oncol* 2005;23:5578–5587.
81. Trigo J, Hitt R, Koralweski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. *J Clin Oncol* 2004;22:S502.
82. Burtless B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 2005;23:8646–8654.
83. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. *Lancet Oncol* 2011;12:333–343.
84. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. *J Clin Oncol* 2003;21:1980–1987.
85. Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). *J Clin Oncol* 2005;23:S5531.
86. Soulieres D. Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash. *Oncology (Williston Park)* 2003;17:29–33.
87. Stewart JS, Cohen EE, Licita L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. *J Clin Oncol* 2009;27:1864–1871.
88. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. *Clin Cancer Res* 2005;11:1434–1440.
89. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 2004;22:2184–2191.
90. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. *Clin Cancer Res* 2007;13:4964–4973.
91. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. *N Engl J Med* 1995;332:712–717.
92. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. *Cancer Res* 2000;60:6359–6366.
93. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* 2000;6:879–885.
94. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. *J Natl Cancer Inst* 2006;98:298–300.
95. Kish JA, Weaver A, Jacobs J, et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. *Cancer* 1984;53:1819–1824.
96. Urba SG, Forastiere AA. Systemic therapy of head and neck cancer: most effective agents, areas of promise. *Oncology (Williston Park)* 1989;3:79–88.
97. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. *J Clin Oncol* 1992;10:1245–1251.
98. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol* 1992;10:257–263.
99. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. *Ann Oncol* 1994;5:521–526.
100. Brownman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. *Semin Oncol* 1994;21:311–319.
101. Glisson BS, Murphy BA, Frenette G, et al. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. *J Clin Oncol* 2002;20:1593–1599.
102. Baur M, Kienzer HR, Schweiger J, et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial. *Cancer* 2002;94:2953–2958.
103. Moosmann P, Egli F, Stahel RA, et al. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. *Onkologie* 2003;26:568–572.
104. Pivot X, Cals L, Cupissol D, et al. Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. *Oncology* 2001;60:66–71.
105. Clark JI, Hofmeister C, Choudhury A, et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. *Cancer* 2001;92:2334–2340.
106. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. *J Clin Oncol* 2001;19:1088–1095.
107. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2005;23:3562–3567.

108. Wells N, Murphy B, Dietrich M, et al. Quality of life and pain assessment for head and neck cancer patients treated on E1395: a comparison of two different cisplatin-based chemotherapy regimens. *Proc Am Soc Clin Oncol* 2002;21.
109. Schrijvers D, Johnson J, Jimenez U, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. *J Clin Oncol* 1998;16:1054-1059.
110. Schrijvers D, Van Herpen C, Kerger J, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. *Ann Oncol* 2004;15:638-645.
111. Hitt R, Jimeno A, Millan JM, et al. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. *Cancer* 2004;101:768-775.
112. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. *J Clin Oncol* 1998;16:1325-1330.
113. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. *Am J Clin Oncol* 2000;23:128-131.
114. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* 2008;359:1116-1127.
115. Mesia R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. *Ann Oncol* 2010;21:1967-1973.
116. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. *Ann Oncol* 2011;22:1078-1087.
117. Licitra L, Storkel S, Kerr KM, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. *Eur J Cancer* 2013;49:1161-1168.
118. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. *J Clin Oncol* 2007;25:2171-2177.
119. Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. *Lancet Oncol* 2013;14:697-710.
120. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2006;64:382-391.
121. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. *J Clin Oncol* 1998;16:3556-3562.
122. Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. *Int J Radiat Oncol Biol Phys* 2001;51:1299-1304.
123. Horwitz EM, Harris J, Langer CJ, et al. Concurrent split course hyperfractionated radiotherapy (HfX RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): Update of RTOG 9911. *J Clin Oncol* 2005;23:S5577.
124. Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? *J Clin Oncol* 2006;24:2653-2658.
125. Fandi A, Bachouchi M, Azli N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. *J Clin Oncol* 2000;18:1324-1330.
126. Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. *Cancer* 1991;68:2120-2124.
127. Yeo W, Leung TW, Leung SF, et al. Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. *Cancer Chemother Pharmacol* 1996;38:466-470.
128. Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. *Ann Oncol* 1998;9:327-329.
129. Yeo W, Leung TW, Chan AT, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. *Eur J Cancer* 1998;34:2027-2031.
130. Tan EH, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. *Ann Oncol* 1999;10:235-237.
131. Fountzilias G, Skarlos D, Athanassiades A, et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 1997;8:451-455.
132. Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. *Ann Oncol* 2002;13:150-156.
133. Ma BB, Tannock IF, Pond GR, et al. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. *Cancer* 2002;95:2516-2523.
134. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. *Ann Oncol* 2002;13:1252-1258.
135. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. *Cancer* 2005;103:569-575.
136. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. *Oral Oncol* 2003;9:361-366.
137. Fandi A, Taamma A, Azli N, et al. Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type. *Head Neck* 1997;19:41-47.
138. Chua DT, Wei WI, Wong MP, et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. *Head Neck* 2008;30:863-867.
139. van Herpen CM, Locati LD, Buter J, et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). *Eur J Cancer* 2008;44:2542-2545.
140. Liu FF. Novel gene therapy approach for nasopharyngeal carcinoma. *Semin Cancer Biol* 2002;12:505-515.
141. Chia MC, Shi W, Li JH, et al. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. *Mol Ther* 2004;9:804-817.
142. Tupchong L, Scott CB, Blitzer PH, et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. *Int J Radiat Oncol Biol Phys* 1991;20:21-28.
143. Huang DT, Johnson CR, Schmidt-Ullrich R, et al. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. *Int J Radiat Oncol Biol Phys* 1992;23:737-742.
144. Lundahl RE, Foote RL, Bonner JA, et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. *Int J Radiat Oncol Biol Phys* 1998;40:529-534.
145. Baxi S, Fury M, Ganly I, et al. Ten years of progress in head and neck cancers. *J Natl Compr Canc Netw* 2012;10:806-810.
146. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Head and Neck Cancers. NCCN Web site. http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. Accessed October 21, 2013.
147. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. *J Natl Cancer Inst* 1999;91:2081-2086.
148. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 2003;349:2091-2098.
149. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. *Lancet* 2000;355:949-955.
150. Adelstein DJ, Leblanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? *J Clin Oncol* 2006;24:2624-2628.
151. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. *N Engl J Med* 1991;324:1685-1690.
152. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. *J Natl Cancer Inst* 1996;88:890-899.
153. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. *Ann Oncol* 2004;15:1179-1186.
154. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. *J Natl Cancer Inst* 1994;86:265-272.
155. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. *J Natl Cancer Inst* 2004;96:1714-1717.
156. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med* 2007;357:1695-1704.
157. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol* 2005;23:8636-8645.

158. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med* 2007;357:1705–1715.
159. Hitt R, Grau JJ, Lopez-Pousa A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). *J Clin Oncol* 2009;27:S6009.
160. Haddad R, O'Neill A, Rabinowitz G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. *Lancet Oncol* 2013;14:257–264.
161. Cohen EEW, Karrison T, Kocherginsky M, et al. DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). *J Clin Oncol* 2012;30:S5500.
162. Zhong LP, Zhang CP, Ren CX, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. *J Clin Oncol* 2013;31:744–751.
163. Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPIN randomized phase II study. *J Clin Oncol* 2013;31:853–859.
164. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. *J Natl Cancer Inst* 1996;88:583–589.
165. Browman GP, Hodson DI, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. *Head Neck* 2001;23:579–589.
166. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol* 2009;92:4–14.
167. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol* 2003;21:92–98.
168. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. *Radiother Oncol* 1997;43:29–37.
169. Quon H, Leong T, Haselour R, et al. Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). *Int J Radiat Oncol Biol Phys* 2011;81:719–725.
170. Robbins KT, Kumar P, Wong FS, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. *Head Neck* 2000;22:687–693.
171. Regine WF, Valentino J, Arnold SM, et al. High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol* 2001;19:3333–3339.
172. Rasch CR, Hauptmann M, Schornagel J, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial. *Cancer* 2010;116:2159–2165.
173. Fountzilas G, Ciuleanu E, Dafni U, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. *Med Oncol* 2004;21:95–107.
174. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. *J Clin Oncol* 2004;22:2856–2864.
175. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. *Lancet* 2003;362:1255–1260.
176. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. U.S. Food and Drug Administration Web site. Updated August 14, 2013. <http://www.fda.gov/drugs/drugsafety/postmarketdrugssafety/informationforpatientsandproviders/ucm126481.htm>.
177. Hoff CM, Lassen P, Eriksen JG, et al. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? Results from the randomized DAHANCA 5 and 7 trials. *Acta Oncol* 2011;50:1006–1014.
178. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. *Radiother Oncol* 2011;100:22–32.
179. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. *J Clin Oncol* 2010;28:2989–2995.
180. Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. *J Clin Oncol* 2012;30:1777–1783.
181. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet* 2006;368:843–854.
182. Brizel DM, Albers ME, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. *N Engl J Med* 1998;338:1798–1804.
183. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. *J Clin Oncol* 2000;18:1458–1464.
184. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. *Lancet Oncol* 2012;13:145–153.
185. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med* 2006;354:567–578.
186. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol* 2010;11:21–28.
187. Pfister DC, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. *J Clin Oncol* 2006;24:1072–1078.
188. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). *J Clin Oncol* 2011;29:S5500.
189. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. *Int J Radiat Oncol Biol Phys* 2003;55:9–98.
190. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. *J Clin Oncol* 1998;16:1310–1317.
191. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. *J Clin Oncol* 2003;21:631–637.
192. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. *J Clin Oncol* 2002;20:2038–2044.
193. Chan AT, Hui EP, Ma BB, et al. A randomized phase II study of concurrent cisplatin-radiotherapy (RT) with or without neoadjuvant chemotherapy using docetaxel and cisplatin in advanced nasopharyngeal carcinoma (NPC). *J Clin Oncol* 2005;23:S5544.
194. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. *J Clin Oncol* 2005;23:6730–6738.
195. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. *J Clin Oncol* 2005;23:6966–6975.
196. Chitapanarux I, Lorvidhaya V, Kammerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. *Eur J Cancer* 2007;43:1399–1406.
197. Huang PY, Cao KJ, Guo X, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. *Oral Oncol* 2012;48:1038–1044.
198. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. *J Clin Oncol* 2005;23:3568–3576.
199. Ma BB, Chan AT. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. *Expert Rev Anticancer Ther* 2006;6:383–394.
200. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. *J Clin Oncol* 2005;23:1118–1124.
201. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. *Int J Radiat Oncol Biol Phys* 2006;64:47–56.
202. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. *Lancet Oncol* 2012;13:163–171.

203. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. *Int J Radiat Oncol Biol Phys* 1996;35:463-469.
204. Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 1995;33:569-577.
205. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. *J Clin Oncol* 2001;19:1350-1357.
206. Bae WK, Hwang JE, Shim HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. *Cancer Chemother Pharmacol* 2010;65:589-595.
207. Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. *J Clin Oncol* 2006;24:3693-3704.
208. McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. *N Engl J Med* 1981;305:982-987.
209. Pfister DG, Strong E, Harrison L, et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. *J Clin Oncol* 1991;9:850-859.
210. Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. *Arch Otolaryngol Head Neck Surg* 1998;124:964-971.
211. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. *Oral Oncol* 1998;34:224-228.
212. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol* 2013;31:845-852.
213. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. *J Natl Cancer Inst* 2009;101:142-152.
214. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. *Cancer* 2000;88:876-883.
215. Licita L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. *J Clin Oncol* 2003;21:327-333.
216. Laccourreye O, Veivers D, Hans S, et al. Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. *Cancer* 2001;92:1504-1511.
217. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. *J Clin Oncol* 2006;24:593-598.
218. Pfister DG, Ridge JA. Induction chemotherapy for larynx preservation: patient selection or therapeutic effect? *J Clin Oncol* 2006;24:540-543.
219. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. *J Natl Cancer Inst* 2009;101:498-506.
220. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. *Cancer* 1987;60:301-311.
221. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. *Int J Radiat Oncol Biol Phys* 1992;23:705-713.
222. Al-Sarraf M, Pajak TF, Byhardt RW, et al. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. *Int J Radiat Oncol Biol Phys* 1997;37:777-782.
223. Weissberg JB, Son YH, Papac RJ, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. *Int J Radiat Oncol Biol Phys* 1989;17:3-9.
224. Haffty BC, Son YH, Sasaki CT, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. *Int J Radiat Oncol Biol Phys* 1993;27:241-250.
225. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. *J Clin Oncol* 2008;26:5518-5523.
226. Haughey BH, Sinha P. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer. *Laryngoscope* 2012;122:S13-S33.
227. Daly ME, Lieskovsky Y, Pawlicki T, et al. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. *Head Neck* 2007;29:211-220.
228. Munter MW, Hoffner S, Hof H, et al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative perchelate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. *Int J Radiat Oncol Biol Phys* 2007;67:651-659.
229. Wang ZH, Yan C, Zhang ZY, et al. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study. *Int J Radiat Oncol Biol Phys* 2011;81:1479-1487.
230. Little M, Schipper M, Feng FY, et al. Reducing xerostomia after chemoradiotherapy for head-and-neck cancer: beyond sparing the parotid glands. *Int J Radiat Oncol Biol Phys* 2012;83:1007-1014.
231. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. *N Engl J Med* 1993;329:390-395.
232. Chambers MS, Posner M, Jones CU, et al. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys* 2007;68:1102-1109.
233. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. *J Clin Oncol* 2000;18:3339-3345.
234. Eisbruch A. Amifostine in the treatment of head and neck cancer: intravenous administration, subcutaneous administration, or none of the above. *J Clin Oncol* 2011;29:119-121.
235. Johnstone PA, Niemtzow RC, Riffenburgh RH. Acupuncture for xerostomia: clinical update. *Cancer* 2002;94:1151-1156.
236. Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of isegagan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. *Int J Radiat Oncol Biol Phys* 2004;58:674-681.
237. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. *J Clin Oncol* 2006;24:5186-5193.
238. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. *J Clin Oncol* 2011;29:2808-2814.
239. Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. *J Clin Oncol* 2011;29:2815-2820.
240. Fitzpatrick PJ. Cancer of the lip. *J Otolaryngol* 1984;13:32-36.
241. Byers RM, O'Brien J, Waxler J. The therapeutic and prognostic implications of nerve invasion in cancer of the lower lip. *Int J Radiat Oncol Biol Phys* 1978;4:215-217.
242. Mackay EN, Sellers AH. A statistical review of carcinoma of the lip. *Can Med Assoc J* 1964;90:670-672.
243. Mohs FE, Snow SN. Microscopically controlled surgical treatment for squamous cell carcinoma of the lower lip. *Surg Gynecol Obstet* 1985;160:37-41.
244. Mendenhall WM, Million RR, Cassisi NJ. Elective neck irradiation in squamous-cell carcinoma of the head and neck. *Head Neck Surg* 1980;3:15-20.
245. Chiu A, Fletcher GH. Incidence and causes of failures to control by irradiation the primary lesions in squamous cell carcinomas of the anterior two-thirds of the tongue and floor of mouth. *Am J Roentgenol Radium Ther Nucl Med* 1973;117:502-508.
246. Wang CC, Biggs PJ. Technical and radiotherapeutic considerations of intraoral cone electron beam radiation therapy for head and neck cancer. *Semin Radiat Oncol* 1992;2:171-179.
247. Rodgers LW Jr., Stringer SP, Mendenhall WM, et al. Management of squamous cell carcinoma of the floor of mouth. *Head Neck* 1993;15:16-19.
248. Pernot M, Hoffstetter S, Peiffert D, et al. Epidermoid carcinomas of the floor of mouth treated by exclusive irradiation: statistical study of a series of 207 cases. *Radiother Oncol* 1995;35:177-185.
249. Byers RM, Weber RS, Andrews T, et al. Frequency and therapeutic implications of "skip metastases" in the neck from squamous carcinoma of the oral tongue. *Head Neck* 1997;19:14-19.
250. Mendenhall WM, Van Cise WS, Bova FJ, et al. Analysis of time-dose factors in squamous cell carcinoma of the oral tongue and floor of mouth treated with radiation therapy alone. *Int J Radiat Oncol Biol Phys* 1981;7:1005-1011.
251. Mendenhall WM, Parsons JT, Stringer SP, et al. T2 oral tongue carcinoma treated with radiotherapy: analysis of local control and complications. *Radiother Oncol* 1989;16:275-281.
252. Wendt CD, Peters LJ, Delclos L, et al. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. *Int J Radiat Oncol Biol Phys* 1990;18:1287-1292.
253. Fein DA, Mendenhall WM, Parsons JT, et al. Carcinoma of the oral tongue: a comparison of results and complications of treatment with radiotherapy and/or surgery. *Head Neck* 1994;16:358-365.
254. Pernot M, Malissard L, Hoffstetter S, et al. The study of tumoral, radiobiological, and general health factors that influence results and complications in a series of 448 oral tongue carcinomas treated exclusively by irradiation. *Int J Radiat Oncol Biol Phys* 1994;29:673-679.

255. Chang DT, Sandow PR, Morris CG, et al. Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? *Head Neck* 2007;29:528–536.
256. Nair MK, Sankaranarayanan R, Padmanabhan TK. Evaluation of the role of radiotherapy in the management of carcinoma of the buccal mucosa. *Cancer* 1988;61:1326–1331.
257. Diaz EM Jr, Holsinger FC, Zuniga ER, et al. Squamous cell carcinoma of the buccal mucosa: one institution's experience with 119 previously untreated patients. *Head Neck* 2003;25:267–273.
258. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. *Head Neck* 2004;26:154–162.
259. Mendenhall WM, Amdur RJ, Hinerman RW, et al. Head and neck mucosal melanoma. *Am J Clin Oncol* 2005;28:626–630.
260. Mendenhall WM, Werning JW, Fernandes R, et al. Ameloblastoma. *Am J Clin Oncol* 2007;30:645–648.
261. Cianchetti M, Sandow PS, Scarborough LD, et al. Radiation therapy for minor salivary gland carcinoma. *Laryngoscope* 2009;119:1334–1338.
262. Sehdev MK, Huvos AG, Strong EW, et al. Proceedings: Ameloblastoma of maxilla and mandible. *Cancer* 1974;33:324–333.
263. Mendenhall WM, Morris CG, Amdur RJ, et al. Retromolar trigone squamous cell carcinoma treated with radiotherapy alone or combined with surgery. *Cancer* 2005;103:2320–2325.
264. Million RR, Cassisi NJ. General principles for treatment of cancers in the head and neck: selection of treatment for the primary site and for the neck. In: Million RR, Cassisi NJ, eds. *Management of Head and Neck Cancer: A Multidisciplinary Approach*, 1st ed. Philadelphia: J. B. Lippincott Company; 1984: 43–62.
265. Overholt SM, Eicher SA, Wolf P, et al. Prognostic factors affecting outcome in lower gingival carcinoma. *Laryngoscope* 1996;106:1335–1339.
266. Byers RM, Anderson B, Schwarz EA, et al. Treatment of squamous carcinoma of the retromolar trigone. *Am J Clin Oncol* 1984;7:647–652.
267. Shibuya H, Horiuchi J, Suzuki S, et al. Oral carcinoma of the upper jaw. Results of radiation therapy. *Acta Radiol Oncol* 1984;23:331–335.
268. Huang CJ, Chao KS, Tsai J, et al. Cancer of retromolar trigone: long-term radiation therapy outcome. *Head Neck* 2001;23:758–763.
269. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for salivary gland carcinoma. *Cancer* 2005;103:2544–2550.
270. Mendenhall WM, Mendenhall CM, Mendenhall NP. Solitary plasmacytoma of bone and soft tissues. *Am J Otolaryngol* 2003;24:395–399.
271. Lindberg RD, Barkley HT Jr, Jesse RH, et al. Evolution of the clinically negative neck in patients with squamous cell carcinoma of the faucial arch. *Am J Roentgenol Radium Ther Nucl Med* 1971;111:60–65.
272. Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for squamous cell carcinoma of the base of tongue. *Am J Clin Oncol* 2006;29:32–39.
273. Steiner W, Fierek O, Ambrosch P, et al. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. *Arch Otolaryngol Head Neck Surg* 2003;129:36–43.
274. Al-Othman MO, Amdur RJ, Morris CG, et al. Does feeding tube placement predict for long-term swallowing disability after radiotherapy for head and neck cancer? *Head Neck* 2003;25:741–747.
275. Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. *Am J Clin Oncol* 2006;29:290–297.
276. Chera BS, Amdur RJ, Hinerman RW, et al. Definitive radiation therapy for squamous cell carcinoma of the soft palate. *Head Neck* 2008;30:1114–1119.
277. Vincent RG, Marchetta F. The relationship of the use of tobacco and alcohol to cancer of the oral cavity, pharynx or larynx. *Am J Surg* 1963;106:501–505.
278. Pillsbury HR, Kirchner JA. Clinical vs histopathologic staging in laryngeal cancer. *Arch Otolaryngol* 1979;105:157–159.
279. Chera BS, Amdur RJ, Morris CG, et al. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. *Int J Radiat Oncol Biol Phys* 2010;78:461–466.
280. Olsen KD, DeSanto LW, Pearson BW. Positive Delphian lymph node: clinical significance in laryngeal cancer. *Laryngoscope* 1987;97:1033–1037.
281. Lederman M. [The place of radiotherapy in the treatment of cancer of the larynx]. *Ann Radiol (Paris)* 1961;4:433–454.
282. Garcia-Serra A, Hinerman RW, Amdur RJ, et al. Radiotherapy for carcinoma in situ of the true vocal cords. *Head Neck* 2002;24:390–394.
283. Mendenhall WM, Werning JW, Hinerman RW, et al. Management of T1-T2 glottic carcinomas. *Cancer* 2004;100:1786–1792.
284. Mendenhall WM, Parsons JT, Stringer SP, et al. Stage T3 squamous cell carcinoma of the glottic larynx: a comparison of laryngectomy and irradiation. *Int J Radiat Oncol Biol Phys* 1992;23:725–732.
285. Mendenhall WM, Parsons JT, Mancuso AA, et al. Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx. *J Clin Oncol* 1997;15:2394–2402.
286. Weinstein GS, El-Sawy MM, Ruiz C, et al. Laryngeal preservation with supracricoid partial laryngectomy results in improved quality of life when compared with total laryngectomy. *Laryngoscope* 2001;111:191–199.
287. Mendenhall WM, Morris CG, Stringer SP, et al. Voice rehabilitation after total laryngectomy and postoperative radiation therapy. *J Clin Oncol* 2002;20:2500–2505.
288. Yamazaki H, Nishiyama K, Tanaka E, et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. *Int J Radiat Oncol Biol Phys* 2006;64:77–82.
289. Gluckman JL, Hamaker RC, Schuller DE, et al. Surgical salvage for stomal recurrence: a multi-institutional experience. *Laryngoscope* 1987;97:1025–1029.
290. Mendenhall WM, Morris CG, Amdur RJ, et al. Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. *Head Neck* 2003;25:535–542.
291. Mancuso AA, Mukherji SK, Schmalfuss I, et al. Preradiotherapy computed tomography as a predictor of local control in supraglottic carcinoma. *J Clin Oncol* 1999;17:631–637.
292. Somerset JD, Mendenhall WM, Amdur RJ, et al. Planned postradiotherapy bilateral neck dissection for head and neck cancer. *Am J Otolaryngol* 2001;22:383–386.
293. Thomas JV, Olsen KD, Neel HB 3rd, et al. Early glottic carcinoma treated with open laryngeal procedures. *Arch Otolaryngol Head Neck Surg* 1994;120:264–268.
294. Som ML. Cordal cancer with extension to vocal process. *Laryngoscope* 1975;85:1298–1307.
295. Foote RL, Olsen KD, Buskirk SJ, et al. Laryngectomy alone for T3 glottic cancer. *Head Neck* 1994;16:406–412.
296. Hinerman RW, Mendenhall WM, Morris CG, et al. T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience. *Am J Clin Oncol* 2007;30:181–185.
297. Pameijer FA, Mancuso AA, Mendenhall WM, et al. Can pretreatment computed tomography predict local control in T3 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy? *Int J Radiat Oncol Biol Phys* 1997;37:1011–1021.
298. Jesse RH. The evaluation of treatment of patients with extensive squamous cancer of the vocal cords. *Laryngoscope* 1975;85:1424–1429.
299. Ogura JH, Sessions DG, Spector CJ. Analysis of surgical therapy for epidermoid carcinoma of the laryngeal glottis. *Laryngoscope* 1975;85:1522–1530.
300. Skolnik EM, Yee KF, Wheatley MA, et al. Carcinoma of the laryngeal glottis therapy and end results. *Laryngoscope* 1975;85:1453–1466.
301. Vermund H. Role of radiotherapy in cancer of the larynx as related to the TNM system of staging. A review. *Cancer* 1970;25:485–504.
302. Stewart JC, Jackson AW. The steepness of the dose response curve both for tumor cure and normal tissue injury. *Laryngoscope* 1975;85:1107–1111.
303. Harwood AR, Beale FA, Cummings BJ, et al. T4N0M0 glottic cancer: an analysis of dose-time volume factors. *Int J Radiat Oncol Biol Phys* 1981;7:1507–1512.
304. Hinerman RW, Mendenhall WM, Amdur RJ, et al. Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection. *Head Neck* 2002;24:456–467.
305. Lee NK, Goepfert H, Wendt CD. Supraglottic laryngectomy for intermediate-stage cancer: U.T. M.D. Anderson Cancer Center experience with combined therapy. *Laryngoscope* 1990;100:831–836.
306. Ambrosch P, Kron M, Steiner W. Carbon dioxide laser microsurgery for early supraglottic carcinoma. *Ann Otol Rhinol Laryngol* 1998;107:680–688.
307. Neel HB 3rd, Devine KD, Desanto LW. Laryngofissure and cordectomy for early cordal carcinoma: outcome in 182 patients. *Otolaryngol Head Neck Surg* (1979) 1980;88:79–84.
308. Kirchner JA. Pyriform sinus cancer: a clinical and laboratory study. *Ann Otol Rhinol Laryngol* 1975;84:793–803.
309. Ogura JH, Biller HF, Wette R. Elective neck dissection for pharyngeal and laryngeal cancers. An evaluation. *Ann Otol Rhinol Laryngol* 1971;80:646–650.
310. Pameijer FA, Mancuso AA, Mendenhall WM, et al. Evaluation of pretreatment computed tomography as a predictor of local control in T1/T2 pyriform sinus carcinoma treated with definitive radiotherapy. *Head Neck* 1998;20:159–168.
311. Rabbani A, Amdur RJ, Mancuso AA, et al. Definitive radiotherapy for T1-T2 squamous cell carcinoma of pyriform sinus. *Int J Radiat Oncol Biol Phys* 2008;72:351–355.
312. Mendenhall WM, Morris CG, Kirwan JM, et al. Definitive radiation therapy for squamous cell carcinoma of the pharyngeal wall. *Prac Radiat Oncol* 2012;2:e113–e119.
313. Marks JE, Kurnik B, Powers WE, et al. Carcinoma of the pyriform sinus. An analysis of treatment results and patterns of failure. *Cancer* 1978;41:1008–1015.
314. Marks JE, Freeman RB, Lee F, et al. Pharyngeal wall cancer: an analysis of treatment results complications and patterns of failure. *Int J Radiat Oncol Biol Phys* 1978;4:587–593.
315. Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 1978;4:182–198.
316. Fletcher GH, Million RR. Malignant tumors of the nasopharynx. *Am J Roentgenol Radium Ther Nucl Med* 1965;93:44–55.
317. Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. *Int J Radiat Oncol Biol Phys* 2002;52:1238–1244.
318. Chow E, Payne D, O'Sullivan B, et al. Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Is combined modality treatment really necessary? *Radiat Oncol* 2002;63:269–274.

319. Leung TW, Tung SY, Sze WK, et al. Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2000;48:1331-1338.
320. Mendenhall WM, Mendenhall CM, Malvapa RS, et al. Re-irradiation of head and neck carcinoma. *Am J Clin Oncol* 2008;31:393-398.
321. Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. *Int J Radiat Oncol Biol Phys* 1992;23:261-270.
322. Leung TW, Tung SY, Sze WK, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. *Head Neck* 2005;27:555-565.
323. Chua DT, Sham JS, Kwong DL, et al. Volumetric analysis of tumor extent in nasopharyngeal carcinoma and correlation with treatment outcome. *Int J Radiat Oncol Biol Phys* 1997;39:711-719.
324. Teo P, Yu P, Lee WY, et al. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. *Int J Radiat Oncol Biol Phys* 1996;36:291-304.
325. Mendenhall WM, Morris CG, Hinerman RW, et al. Definitive radiotherapy for nasopharyngeal carcinoma. *Am J Clin Oncol* 2006;29:622-627.
326. Bhandare N, Monroe AT, Morris CG, et al. Does altered fractionation influence the risk of radiation-induced optic neuropathy? *Int J Radiat Oncol Biol Phys* 2005;62:1070-1077.
327. Monroe AT, Bhandare N, Morris CG, et al. Preventing radiation retinopathy with hyperfractionation. *Int J Radiat Oncol Biol Phys* 2005;61:856-864.
328. Monroe AT, Hinerman RW, Amdur RJ, et al. Radiation therapy for esthesioneuroblastoma: rationale for elective neck irradiation. *Head Neck* 2003;25:529-534.
329. Gomez JA, Mendenhall WM, Tannehill SP, et al. Radiation therapy in inverted papillomas of the nasal cavity and paranasal sinuses. *Am J Otolaryngol* 2000;21:174-178.
330. Mendenhall WM, Mendenhall CM, Riggs CE Jr., et al. Sinonasal undifferentiated carcinoma. *Am J Clin Oncol* 2006;29:27-31.
331. Mendenhall WM, Mendenhall CM, Werning JW, et al. Adult head and neck soft tissue sarcomas. *Head Neck* 2005;27:916-922.
332. Mendenhall WM, Olivier KR, Lynch JW Jr., et al. Lethal midline granuloma-nasal natural killer/T-cell lymphoma. *Am J Clin Oncol* 2006;29:202-206.
333. Wallace A, Morris CG, Kirwan J, et al. Radiotherapy for squamous cell carcinoma of the nasal vestibule. *Am J Clin Oncol* 2007;30:612-616.
334. Weessler MC, Montgomery WW, Turner PA, et al. Inverted papilloma. *Ann Otol Rhinol Laryngol* 1986;95:215-221.
335. Mendenhall WM, Amdur RJ, Morris CG, et al. Carcinoma of the nasal cavity and paranasal sinuses. *Laryngoscope* 2009;119:899-906.
336. Goepfert H, Guillaumondegui OM, Jesse RH, et al. Squamous cell carcinoma of nasal vestibule. *Arch Otolaryngol* 1974;100:8-10.
337. Elkon D, Hightower SI, Lim ML, et al. Esthesioneuroblastoma. *Cancer* 1979;44:1087-1094.
338. Waldron JN, O'Sullivan B, Gullane P, et al. Carcinoma of the maxillary antrum: a retrospective analysis of 110 cases. *Radiother Oncol* 2000;57:167-173.
339. Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. *Int J Radiat Oncol Biol Phys* 1994;30:765-773.
340. Parsons JT, Bova FJ, Fitzgerald CR, et al. Severe dry-eye syndrome following external beam irradiation. *Int J Radiat Oncol Biol Phys* 1994;30:775-780.
341. Woods CI, Strasnick B, Jackson CG. Surgery for glomus tumors: the Otolaryngology Group experience. *Laryngoscope* 1993;103:65-70.
342. Green JD Jr., Brackmann DE, Nguyen CD, et al. Surgical management of previously untreated glomus jugulare tumors. *Laryngoscope* 1994;104:917-921.
343. Bhandare N, Antonelli PJ, Morris CG, et al. Ototoxicity after radiotherapy for head and neck tumors. *Int J Radiat Oncol Biol Phys* 2007;67:469-479.
344. Hinerman RW, Indelicato DJ, Amdur RJ, et al. Cutaneous squamous cell carcinoma metastatic to parotid-area lymph nodes. *Laryngoscope* 2008;118:1989-1996.
345. Gallia LJ, Johnson JT. The incidence of neoplastic versus inflammatory disease in major salivary gland masses diagnosed by surgery. *Laryngoscope* 1981;91:512-516.
346. Gullane PJ, Havas TJ. Facial nerve grafts: effects of postoperative irradiation. *J Otolaryngol* 1987;16:112-115.
347. Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. *Int J Radiat Oncol Biol Phys* 1993;27:235-240.
348. Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. *Arch Otolaryngol Head Neck Surg* 2009;135:687-692.
349. Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. *Crit Rev Oncol Hematol* 2010;74:134-148.
350. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. *Head Neck Surg* 1986;8:177-184.
351. Hodge CW, Morris CG, Werning JW, et al. Role of radiotherapy for pleomorphic adenoma. *Am J Clin Oncol* 2005;28:148-151.
352. Spiro RH, Huvos AG, Strong EW. Cancer of the parotid gland. A clinicopathologic study of 288 primary cases. *Am J Surg* 1975;130:452-459.
353. Woods JE, Chong GC, Beahrs OH. Experience with 1,360 primary parotid tumors. *Am J Surg* 1975;130:460-462.
354. Garden AS, el-Naggar AK, Morrison WH, et al. Postoperative radiotherapy for malignant tumors of the parotid gland. *Int J Radiat Oncol Biol Phys* 1997;37:79-85.
355. Byers RM, Jesse RH, Guillaumondegui OM, et al. Malignant tumors of the submaxillary gland. *Am J Surg* 1973;126:458-463.
356. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. *J Clin Oncol* 2006;24:2673-2678.
357. Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. *Lancet Oncol* 2011;12:815-824.
358. Mattox DE, Von Hoff DD, Balcerzak SP. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck. *Invest New Drugs* 1990;8:105-107.
359. Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. *Ann Oncol* 1993;4:785-788.
360. Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. *Ann Oncol* 1996;7:867-869.
361. Airolli M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. *Cancer* 2001;91:541-547.
362. Licitra L, Marchini S, Spinazze S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. *Cancer* 1991;68:1874-1877.
363. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. *Head Neck* 2006;28:197-204.
364. Alcedo JC, Fabrega JM, Arosemena JR, et al. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. *Head Neck* 2004;26:829-831.
365. Faivre S, Raymond E, Casiraghi O, et al. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. *J Clin Oncol* 2005;23:6271-6273.
366. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. *J Clin Oncol* 2005;23:585-590.
367. Slevin NJ, Mais KL, Bruce I, et al. Imatinib with cisplatin in recurrent and/or metastatic salivary adenoidcystic carcinoma - response assessed by FDG-PET scanning. *J Clin Oncol* 2004;22:S5604.
368. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. *Oral Oncol* 2003;9:724-727.
369. Locati LD, Bossi B, Rinaldi GR, et al. Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC). Poster presented at: 2005 3rd International Symposium in Targeted Anticancer Therapies; March 3-5, 2005; Amsterdam.
370. Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. *Proc Natl Acad Sci U S A* 2009;106:18740-18744.
371. Dillon PM, Moskaluk C, Fracasso PM, et al. Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma. *J Clin Oncol* 2013;31:S6021.
372. Mendenhall WM, Mendenhall CM, Werning JW, et al. Salivary gland pleomorphic adenoma. *Am J Clin Oncol* 2008;31:95-99.
373. Spiro RH, Koss LG, Hajdu SI, et al. Tumors of minor salivary origin. A clinicopathologic study of 492 cases. *Cancer* 1973;31:117-129.
374. Wallace AS, Morris CG, Kirwan JM, et al. Radiotherapy for pleomorphic adenoma. *Am J Otolaryngol* 2013;34:36-40.